Market Overview

Morning Market Losers

Related SNTA
Synta Announces Presentation of Results from an Investigator-Sponsored Phase 1 Trial of Ganetespib in HER2+ Metastatic Breast Cancer
Synta Announces FDA's Oncologic Drugs Advisory Committee to Discuss Pediatric Uses for Ganetespib
Related INFI
Infinity Announces Clinical And Preclincal Data For Duvelisib To Be Presented at ASH 2014 Annual Meeting
Infinity Reports Topline Data From Phase 2a Exploratory Study Of Duvelisib In Patients With Mild, Allergic Asthma

Synta Pharmaceuticals (NASDAQ: SNTA) shares dipped 32.93% to $4.95 after the company reported positive overall survival results from GALAXY-1 Phase 2b/3 trial of ganetespib in second-line non-small cell lung cancer.

Infinity Pharmaceuticals (NASDAQ: INFI) shares lost 23.41% to $20.64 on Phase 1 data.

Affymax (NASDAQ: AFFY) fell 22.60% to $1.61. Affymax's PEG ratio is -0.17.

National Bank of Greece SA (NYSE: NBG) dropped 12.60% to $6.31. The bank's trailing-twelve-month profit margin is -98.37%

Posted-In: Morning Market LosersNews Movers & Shakers Intraday Update Markets

 

Related Articles (AFFY + INFI)

Around the Web, We're Loving...

Get Benzinga's Newsletters